胃癌，作为最常见的消化道恶性肿瘤之一，总生存率很低【1】。目前手术认为

Gastric cancer, as one of the most common malignant tumors of the digestive tract, has a very low overall survival rate [1]. Surgery is currently considered to be the only radical treatment for gastric cancer. <br><br>With the progress of surgical technology and the implementation of traditional radiotherapy, chemotherapy and neoadjuvant therapy, the 5-year survival rate of early gastric cancer can reach> 95% [2]. <br><br>Despite this, most patients have no specific symptoms in the early stage, but most of them are locally advanced at the time of treatment, so they miss the optimal surgical window. <br><br>Therefore, the main treatment methods for advanced gastric cancer are palliative gastrectomy, radiotherapy and chemotherapy [3], molecular targeted therapy and immunotherapy [4]. <br><br>In recent years, domestic and foreign studies have shown that for patients with advanced malignant tumors, immunotherapy can reduce the inflammatory response, reduce the level of tumor markers, and improve the immune function of patients with T lymphocytes [5]. <br><br>It was considered in the study by Hu et al. [6] that due to changes in humoral and cellular immune functions, the patient's physical fitness and rehabilitation can be significantly improved. <br><br>In this study, immunotherapy combined with chemotherapy was used to treat patients with locally advanced gastric cancer, and the patient's immune function, physical status, and nutritional status were significantly improved. The clinical efficacy of patients with immunotherapy combined with chemotherapy is significantly higher than that of chemotherapy alone. <br><br>The specific details are reported as follows:

Stomach cancer, as one of the most common gastrointestinal malignancies, has a very low overall survival rate. At present, surgery is considered to be the only cure for stomach cancer.<br><br>With advances in surgical techniques and the implementation of traditional radiotherapy, chemotherapy and new complementary therapies, the five-year survival rate for early gastric cancer can reach >95%.<br><br>Despite this, most patients have no specific symptoms at an early stage, but are mostly locally advanced at the time of treatment and therefore miss the best surgical window.<br><br>Therefore, the main treatment methods for advanced stomach cancer are palliative gastric excision, chemotherapy, molecular targeted therapy and immunotherapy.<br><br>In recent years, studies at home and abroad have shown that immunotherapy can reduce inflammatory response, reduce tumor marker level and improve patients' Immune function of T lymphocytes.<br><br>It is believed in Studies such as Hu and others that patients' physical fitness and rehabilitation can be significantly improved due to changes in body fluid immunity and cellular immune function.<br><br>In this study, immunotherapy combined chemotherapy was used to treat patients with local advanced stomach cancer, and their immune function and physical and nutritional status improved significantly. The clinical efficacy of patients with immunotherapy combined chemotherapy was significantly higher than that of chemotherapy alone.<br><br>Details are reported below:

Gastric cancer, as one of the most common gastrointestinal malignancies, has a low overall survival rate [1]. At present, surgery is considered to be the only radical treatment for gastric cancer.<br>With the progress of surgical technology and the implementation of traditional radiotherapy, chemotherapy and neoadjuvant therapy, the 5-year survival rate of early gastric cancer can reach > 95% [2].<br>However, most patients have no specific symptoms in the early stage, but most of them are locally advanced, so they miss the best operation window.<br>Therefore, palliative gastrectomy, chemoradiotherapy, molecular targeted therapy and immunotherapy are the main treatment methods for advanced gastric cancer.<br>In recent years, studies at home and abroad have shown that immunotherapy can reduce the inflammatory response, reduce the level of tumor markers, and improve the immune function of T lymphocytes in patients with advanced cancer [5].<br>In the research of Hu et al. [6], it is believed that the physical fitness and rehabilitation of patients can be significantly improved due to the changes of humoral and cellular immune functions.<br>In this study, immunotherapy combined with chemotherapy was used to treat patients with locally advanced gastric cancer. The immune function, physical status and nutritional status of patients were significantly improved. The clinical efficacy of immunotherapy combined with chemotherapy was significantly higher than that of chemotherapy alone.<br>The details are as follows:<br>